To test if PD-1 blockade increased the efficacy of solid tumor TCR-T cell therapy in a murine model, B16F10 melanoma tumors with stable expression of a mKate2-SIINFEKL fusion protein (B16-K-OVA) were treated with H-2Kb:SIINFEKL-specific OT-I TCR transgenic T cells. This evidence concerns the gene PDCD1 and melanoma.